Answers are grounded in this paper and cite their sources.
In vitro analysis shows bexarotene activates gut-homing receptors in B and T lymphocytes, suggesting immune modulation.
Background Retinoic acid (RA) receptors (RARs) in human lymphocytes modulate the humoral and intestinal immune response by regulating target genes, including CD38, TGM2, and gut-homing markers. The impact of retinoid X receptors (RXRs) on this process is elusive. Objective To determine the impact of the RXR ligand bexarotene (BXR) on the activation and differentiation of human B and T lymphocytes. Methods In vitro BXR stimulation of human CD19 + B cells and CD4 + T helper cells was investigated regarding retinoid target gene expression using qPCR and flow cytometry and validated in peripheral B and T lymphocytes of patients with cutaneous T-cell lymphoma (CTCL) with and without BXR treatment. Results BXR induced the canonical retinoid target gene CD38 in B cells and T cells (sixfold and threefold, respectively). BXR increased CD38 surface protein expression on B cells twofold and plasmablast differentiation threefold. The frequency of the gut-homing receptors CCR9 and integrin β7 was doubled on T and B cells after BXR stimulation, while cutaneous leucocyte-associated antigen (CLA) expression was decreased in B cells. Under BXR treatment, a reduced frequency of cells with these gut-homing receptors was observed in the blood of CTCL patients regarding memory T cells (mean off: 1.9%; on: 0.6%) and B cells (mean off: 5.7%, on: 4%). Conclusion BXR via RXRs directly targets B and T lymphocytes, inducing retinoid target gene expression, including gut-homing receptors.
No takes yet. Share an insight, caveat, or question.
Kaiser et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: